---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-028690"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:23:33.004761+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion's CLEAR Outcomes trial shows NEXLETOL reduces CV risk 13-23% in statin-intolerant patients

## Summary
- NEXLETOL reduced MACE-4 by 13% (p=0.004), MACE-3 by 15% (p=0.006), heart attack by 23% (p=0.002), and coronary revascularization by 19% (p=0.001) vs placebo.
- First LDL-C lowering therapy since statins to reduce hard ischemic events in both primary and secondary prevention patients.
- Regulatory filings to FDA and EMA expected in 1H 2023; potential partner milestone payments up to $440M ($300M EU label, $140M other milestones).
- Full-year 2023 operating expenses guided at $225M-$245M, including $25M non-cash stock compensation.
- Results published in NEJM and presented at ACC.23/WCC; conference call scheduled for March 6, 2023.

## SEC filing metadata
- accession: 0001104659-23-028690
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465923028690/0001104659-23-028690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465923028690/tm238559d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-028690
- JSON: https://secwatch.observer/filing/0001104659-23-028690.json
- Plain text: https://secwatch.observer/filing/0001104659-23-028690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.